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Lactobacillus paracasei F19 is an emerging probiotic strain that shows considerable promise for use in functional foods for intestinal
health. In a multicentre European research project, human feeding trials provided an insight into the ability of this strain to survive
gastric transit and transiently colonize the human intestinal tract. Analysis of the faecal microbiota in healthy human volunteers showed
that a proportion of the subjects carried a strain indistinguishable from L. paracasei F19 naturally within their intestines. When consumed
in different foods, L. paracasei F19 survived gastric transit in healthy infants, adults, and elderly subjects. The bacterium transiently
colonized both the colonic lumen and mucosa. Molecular analysis of faecal and colonic biopsy samples from children fed the probiotic
showed that L. paracasei F19 did not perturb the population dynamics of other major populations of bacteria in the intestinal microbiota.
This strain was well tolerated by young children, healthy adults, adults with milk-hypersensitivity and elderly subjects infected with
Helicobacter pylori. Key words : F19, Lactobacillus, microbiota, paracasei, probiotic, survival.
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INTRODUCTION
Probiotics are live microorganisms included in foods to
provide health bene ts to consumers by positively con-
tributing to the composition and activity of their intestinal
microbiota (1). A number of bacteria from the genera
Lactobacillus and Bi dobacterium have been identi ed as
having characteristics necessary for probiotic action. These
properties include technological parameters, survival dur-
ing passage through the upper gastrointestinal tract, tran-
sient persistence in the intestinal tract, and proven safety
for human consumption (2–4). Health bene ts to humans
are strain speci c, with different probiotic organisms
providing varying effects on health parameters such as
immunomodulation and protection against intestinal infec-
tions (5).
Lactobacillus paracasei ssp. paracasei isolate F19 (Lacto -
bacillus F19) is an emerging probiotic strain that is readily
amenable to commercial manufacture and which retains
viability and functionality in dairy products while provid-
ing good  avour and organoleptic properties (6). This
strain has shown considerable promise during in ×itro trials
assessing its potential to survive gastric transit and to
persist in the colonic environment (unpublished data). As
part of a multicentre European project named PROB-
DEMO (described in (7)), L. paracasei was included in
human pilot studies to assess the ability of probiotics to
survive intestinal transit and to examine their in uence on
the native microbiota of consumers. Subjects in the trials
were also monitored for any deleterious effects resulting
from probiotic consumption. The current paper outlines
the results of trials involving Lactobacillus F19, focusing
on its survival, ecology and safety in the human intestinal
tract.
HUMAN FEEDING STUDIES
Four pilot feeding studies assessing Lactobacillus F19 were
conducted within the PROBDEMO project, involving vol-
unteers from Finland and Sweden (Table I). A variety of
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target groups were tested, ranging in age from infants to
the elderly, and including both healthy subjects and indi-
viduals with mild health disorders. The probiotic delivery
systems included capsules and milk containing freeze-dried
Lactobacillus F19, and milk and yoghurt fermented by
mesophilic or yoghurt cultures including Lactobacillus
F19. In each case, samples of the product were tested to
ensure delivery of viable and functionally active probiotic
bacteria to the volunteers throughout the trials.
Pre×alence of Lactobacillus F19 in the nati×e intestinal
microbiota of humans
The intestinal microbiota of humans is complex, contain-
ing more than 400 different species of bacteria and possi-
bly many thousands of strains (8, 9). Modern molecular
techniques such as PCR and restriction fragment length
polymorphism (RFLP) analysis allow researchers to iden-
tify individual strains within the intestinal microbiota.
Lactobacillus F19 was originally isolated from the small
intestine of a human subject. This strain was not produced
commercially at the time of the trials described in this
report, and therefore, the subjects were not previously
exposed to this strain in probiotic foods. Despite this,
strains indistinguishable from Lactobacillus F19 using
RAPD (randomly ampli ed polymorphic DNA) analysis
were identi ed in the initial baseline sample (pre-adminis-
tration) of one of the individuals in Trial B, and in three
samples from one individual in the control group in Trial
D. Therefore, Lactobacillus F19, or at least very closely
related strains, are present in the native intestinal micro-
biota of a small proportion of individuals from Nordic
countries. This enables further con dence in the strain’s
safety and its ability to persist in the intestinal tract of
humans.
Earlier research investigating the diversity of strains of
lactobacilli and bi dobacteria within humans failed to  nd
common strains among 10 people, suggesting that individ-
uals may harbour distinct populations of these bacteria
within their intestinal tracts (10). In contrast, the
PRODEMO studies suggest that strains closely related to
Lactobacillus F19 are present in the intestinal tract of a
small percentage of the population in northern Europe.
Sur×i×al of Lactobacillus F19 in the human intestinal tract
If a probiotic bacterium is to bene cially contribute to the
activity of the intestinal microbiota it must successfully
survive transit through the harsh gastric environment, and
then tolerate bile released into the small intestine that can
also reduce bacterial viability. Trials conducted using a
sophisticated in ×itro model of the intestinal tract at TNO
in the Netherlands indicated that Lactobacillus F19 can be
expected to survive intestinal transit (11). In order to
con rm intestinal transit survival in humans, analysis of
faecal samples was conducted prior to and following pro-
biotic ingestion.
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RAPD analysis using validated primers for the speci c
detection of Lactobacillus F19 in intestinal samples was
developed in order to identify this strain among the myr-
iad of strains present in the intestinal microbiota. In each
of the four trials described in Table I, faecal samples were
cultured for total lactobacilli using Rogosa agar and then
colonies resembling Lactobacillus F19 were analysed using
RAPD to con rm their identity. In all of the age groups
tested, from 1-year-old infants to subjects \85 years of
age, Lactobacillus F19 could be identi ed in faecal samples
following ingestion. During ingestion of the probiotic,
Lactobacillus F19 was the numerically dominant Lacto -
bacillus isolated in faecal samples (Table II). This con-
 rmed that Lactobacillus F19 survived intestinal transit
and could transiently colonize the intestinal tract of hu-
mans. When monitoring of faecal microbiota was contin-
ued following cessation of probiotic consumption in Trials
A and D, six infants were colonized by Lactobacillus F19
2 weeks after consumption, and two elderly subjects re-
mained colonized after 8 weeks (12, 13). This shows that
Lactobacillus F19 can colonize the intestinal tract of some
individuals for relatively long periods following the cessa-
tion of probiotic intake.
Adhesion to the intestinal mucosa is considered a desir-
able characteristic for potential probiotic bacteria, possibly
aiding colonization and probiotic action including im-
munomodulation (14, 15). In Trial B, samples that repre-
sented the colonic lumen (faecal) and the colonic mucosa
(biopsy) were collected in order to determine the intestinal
location of the bacteria. Biopsy samples were washed prior
to microbiological analysis so that only bacteria adhering
to the mucosa were enumerated. Although in ×itro studies
using mucus from the intestinal mucosa have indicated
that adhesion to intestinal mucus by Lactobacillus F19 was
moderate to poor compared with other intestinal bacteria
tested (16, 17), the results of Trial B (Table II) indicate
that Lactobacillus F19 was both in the lumen and adhering
to the mucosa of the colon following consumption. In
contrast to most faecal samples, Lactobacillus F19 only
dominated the Lactobacillus community on the mucosa in
two of  ve volunteers. This may re ect colonization resis-
tance by the indigenous mucosal microbiota of some indi-
viduals, or may be the normal distribution of Lactobacillus
F19 within its niche´ in the colon. Mucosal biopsies taken
from the ascending, transverse, and descending colon con-
tained similar levels of Lactobacillus F19 (data not shown),
demonstrating that it can colonize the length of the colon.
Trials involving adhesive and non-adhesive isogenic mu-
tants of Lactobacillus crispatus showed that after ingestion
by humans, the adhesive strain colonized the intestinal
mucosa (biopsy samples) and persisted longer in the intes-
tinal tract (18). The ability of Lactobacillus F19 to adhere
to intestinal mucosa may provide it too with an advantage
in colonizing the human intestinal tract.
Effects on other intestinal bacteria
One of the proposed bene ts of probiotics is to prevent
overgrowth or colonization by deleterious microorganisms
within the intestinal tract following perturbations to the
microbial ecosystem. It follows that it is undesirable for an
exogenous probiotic to disturb the microbial balance in the
intestinal tract of healthy individuals. Techniques such as
PCR using universal bacterial primers, coupled with dena-
turing gradient gel electrophoresis (DGGE), allow visual-
ization of the major groups of bacteria within the
intestinal microbiota (19). Samples from Trial A ( ve from
different individuals in the placebo group and  ve from
the treatment group) were analysed before and after feed-
ing. The subjects were young children, an age group for
whom it is known that the composition of the intestinal
microbiota is still developing and is relatively unstable
(20). Some changes were observed in the microbiota com-
position in the individuals tested in Trial A (Fig. 1).
However, none correlated with the consumption of Lacto -
bacillus F19, indicating that this probiotic does not disturb
the balance of major population groups within the intesti-
nal microbiota. A band for Lactobacillus F19 was not
visible on the gel suggesting that, while Lactobacillus F19
dominated the luminal Lactobacillus population during
treatment, it constituted less than 1% of the total bacterial
Table II
Numbers of total lactobacilli and the probiotic strain Lactobacillus F19 in faecal and colonic mucosal samples from  ×e healthy adult humans
prior to and following 12 days of consumption of the probiotic in yoghurt at approximately 4½10 10 CFU day
Lactobacillus F19aSample Total lactobacilli
average CFU g (9SD)average CFU g (9SD)
Faeces prior to administration of the probiotic None detected in four individuals.2.2 (93.5)½106
1.2½104 in one individual
Faeces after 12 days of consumption of the probiotic 2.0 (91.3)½106 1.3 (91.5)½106
0.9 (91.7)½105bColonic mucosal biopsy after 12 days of consumption of 0.9 (91.7)½104b
the probiotic
a Strain speci c RAPD PCR used to identify Lactobacillus F19 from colonies with a L. paracasei appearance.
b CFU biopsy samples (colonic mucosal section approximately 3 mm in diameter).
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Fig. 1. DGGE pro les of PCR prod-
ucts obtained using primers 968-GCf
and 1401r on total DNA isolated from
faecal samples. The samples of individ-
ual children in Trial A, fed with L.
paracasei F19 (F19) or placebo (P) were
taken pre (0) and post-administration (3
and 5 weeks). The DGGE pattern of L.
paracasei F19 is indicated (courtesy of
GHJ Heilig, EE Vaughan, ADL Akker-
mans, WM de Vos).
population in the intestinal tract. Recently, speci c PCR-
DGGE has been developed for intestinal bi dobacteria and
the Lactobacillus group (21, 22). Analysis of the speci c
Lactobacillus population in faecal samples of children indi-
cated that it is rather unstable, like the dominant community
(22). Furthermore, using this approach the Lactobacillus
F19 strain was detected throughout the feeding period of
children (Trial A), and again provided support for the
natural presence of the Lactobacillus F19 strain within the
intestinal community.
SAFETY OF Lactobacillus F19
Included in each of the trials were observations monitoring
of potential side-effects of probiotic consumption. These
included intestinal discomfort, increased  atulence, and
changes in stool consistency and frequency. The trials
included healthy subjects, adults with veri ed milk-hyper-
sensitivity, and elderly people infected with Helicobacter
pylori. No adverse effects of probiotic administration were
observed in any of the pilot studies. The probiotic was well
tolerated by all individuals (a total of 85 subjects consumed
the probiotic) including those in Trial D, in which the
probiotic was consumed daily for 3 months without adverse
effects. The fact that no side-effects were detected in subjects
ranging in age from 1 to \85 years, and in healthy
individuals and subjects suffering mild illnesses (milk-hyper-
sensitivity and H. pylori infection) suggests that Lactobacil -
lus F19 is a safe microbial food supplement. Adding weight
to this argument are the strain’s origin from the intestinal
tract of a healthy human and its natural prevalence in a
healthy human population.
CONCLUSIONS
Lactobacillus F19 is an emerging probiotic with good
technological characteristics. It now has a proven ability to
survive gastric transit and to persist in the colonic environ-
ment of humans. This was achieved in subjects over a wide
range of ages from the very young (1 year) to the very old
(\85years), and with four different food delivery matrices.
It appears that Lactobacillus F19 is indigenous to the
intestinal tract of a portion of the population in Finland in
Sweden. This, combined with the absence of deleterious
effects during the human feeding trials, even in subjects with
underlying disorders, suggests that the strain is safe for use
as a human probiotic. The way forward is open for further
clinical testing of this strain to assess its ef cacy in contribut-
ing to improved human health. As for all probiotics,
identifying health bene ts stemming from ingestion of
Lactobacillus F19 against speci c intestinal disorders, and
determining their mechanisms of action are the pending
research challenges.
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